Catalyst Funds Management Pty Ltd Lowers Holdings in HUTCHMED (China) Limited Sponsored ADR $HCM

Catalyst Funds Management Pty Ltd lessened its stake in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 21.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 109,845 shares of the company’s stock after selling 29,903 shares during the quarter. Catalyst Funds Management Pty Ltd’s holdings in HUTCHMED were worth $1,653,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of HUTCHMED by 23.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after purchasing an additional 2,916 shares in the last quarter. Vident Advisory LLC boosted its holdings in shares of HUTCHMED by 78.3% in the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock worth $297,000 after buying an additional 8,664 shares during the last quarter. ABN Amro Investment Solutions bought a new stake in shares of HUTCHMED during the 2nd quarter valued at $962,000. Goldman Sachs Group Inc. grew its holdings in HUTCHMED by 8.5% during the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the period. Finally, XY Capital Ltd grew its stake in shares of HUTCHMED by 142.4% during the 1st quarter. XY Capital Ltd now owns 113,136 shares of the company’s stock valued at $1,702,000 after acquiring an additional 66,460 shares during the period. 8.82% of the stock is owned by institutional investors.

HUTCHMED Stock Down 0.9%

Shares of NASDAQ HCM opened at $14.53 on Thursday. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $19.50. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average is $15.64 and its two-hundred day moving average is $15.64.

Analyst Ratings Changes

HCM has been the subject of a number of analyst reports. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Sunday. Zacks Research lowered HUTCHMED from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 9th. Morgan Stanley cut HUTCHMED from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $18.00 to $13.75 in a report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.